Inhibiting interferon pathways in dermatomyositis: rationale and preliminary evidence.
Autoimmune diseases
JAK-STAT
interferon
muscle disease
myositis
Journal
Current treatment options in rheumatology
ISSN: 2198-6002
Titre abrégé: Curr Treatm Opt Rheumatol
Pays: Switzerland
ID NLM: 101649954
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
medline:
1
9
2021
pubmed:
1
9
2021
entrez:
17
7
2023
Statut:
ppublish
Résumé
Dermatomyositis (DM) is a systemic autoimmune disease affecting multiple organs, including skeletal muscle, skin, and lungs. Although DM disease mechanisms are incompletely understood, accumulating evidence suggests that interferons may play a significant role. Consequently, it is of considerable interest that drugs blocking the activity of interferons by inhibiting the Janus Kinase/Signal Transducer and Activator of Transcription (JAK-STAT) pathway have been approved for use in other autoimmune diseases. This manuscript will examine the IFN pathways and their importance in DM, review the existing literature on the use of JAK-STATs inhibitors in patients with adult or juvenile DM, and discuss the potential utility of JAK-STAT inhibitors to treat this disease. Recent reports suggest that muscle and skin involvement in patients with either adult or juvenile DM respond favorably to JAK-STAT inhibitors. Moreover, preliminary data indicates that JAK-STAT inhibitors may be useful to treat clinical manifestations of this disease that are complicated to manage otherwise, such as calcinosis or rapidly progressive interstitial lung disease in DM patients with anti-MDA5 autoantibodies. An increasing number of reports suggest that JAK-STAT inhibitors may be useful to treat the varied manifestations of adult and juvenile DM. However, as most studies were either small or lacked appropriate comparators, further research will be necessary to define the role of these drugs in DM treatment.
Identifiants
pubmed: 37456764
doi: 10.1007/s40674-021-00182-1
pmc: PMC10348776
mid: NIHMS1862415
doi:
Types de publication
Journal Article
Langues
eng
Pagination
258-271Subventions
Organisme : Intramural NIH HHS
ID : ZIA AR041203
Pays : United States
Déclaration de conflit d'intérêts
Conflict of Interest Maria Casal-Dominguez, IngoPinal-Fernandez, and Andrew L. Mammen declare that they have no conflict of interest
Références
Arthritis Rheum. 2007 Nov;56(11):3784-92
pubmed: 17968926
Medicine (Baltimore). 2012 Jul;91(4):220-228
pubmed: 22732950
Brain. 2016 Jul;139(Pt 7):1891-903
pubmed: 27190020
Brain. 2019 Mar 1;142(3):e8
pubmed: 30715143
Arthritis Rheum. 2009 Jun;60(6):1815-24
pubmed: 19479879
Ann Rheum Dis. 2017 Jun;76(6):998-1008
pubmed: 27993829
J Med Chem. 2014 Jun 26;57(12):5023-38
pubmed: 24417533
N Engl J Med. 2014 Dec 25;371(26):2537-8
pubmed: 25539124
Arthritis Rheum. 2009 Jul;60(7):2193-200
pubmed: 19565506
RMD Open. 2019 Feb 26;5(1):e000811
pubmed: 30886734
Arthritis Care Res (Hoboken). 2017 Nov;69(11):1771-1776
pubmed: 28085235
Immunol Rev. 2009 Mar;228(1):273-87
pubmed: 19290934
Annu Rev Biochem. 1998;67:227-64
pubmed: 9759489
Brain. 2018 Jun 1;141(6):1609-1621
pubmed: 29741608
Brain. 2019 Nov 1;142(11):e59
pubmed: 31603187
PLoS One. 2012;7(1):e29161
pubmed: 22235269
J Immunol. 2010 May 1;184(9):5298-307
pubmed: 20363976
N Engl J Med. 2010 Sep 16;363(12):1117-27
pubmed: 20843246
Medicine (Baltimore). 2020 Sep 11;99(37):e21943
pubmed: 32925726
J Pediatr. 2001 May;138(5):763-6
pubmed: 11343059
Eur J Dermatol. 2007 Jul-Aug;17(4):345-6
pubmed: 17540652
Genes Immun. 2012 Apr;13(3):207-13
pubmed: 21881594
JAMA Dermatol. 2016 Aug 1;152(8):944-5
pubmed: 27120749
N Engl J Med. 2013 Jan 10;368(2):161-70
pubmed: 23301733
N Engl J Med. 2012 Mar 1;366(9):799-807
pubmed: 22375971
J Clin Rheumatol. 2021 Dec 1;27(8S):S574-S577
pubmed: 30614890
J Autoimmun. 2019 Jun;100:131-136
pubmed: 30862449
J Immunol. 2013 Oct 1;191(7):3568-77
pubmed: 24006460
J Interferon Cytokine Res. 2014 Aug;34(8):559-76
pubmed: 25084173
Nat Rev Mol Cell Biol. 2002 Sep;3(9):651-62
pubmed: 12209125
Arthritis Rheum. 2004 Jul;50(7):2281-90
pubmed: 15248228
Eur J Paediatr Neurol. 2002;6 Suppl A:A41-6; discussion A55-8
pubmed: 12365360
Neurology. 2019 Sep 17;93(12):e1193-e1204
pubmed: 31434690
Nat Rev Rheumatol. 2011 May;7(5):297-306
pubmed: 21468145
Mol Med. 2007 Jan-Feb;13(1-2):59-68
pubmed: 17515957
Semin Arthritis Rheum. 2017 Feb;46(4):e19
pubmed: 27642158
Expert Rev Clin Immunol. 2018 Sep;14(9):719-730
pubmed: 30118353
Ann Rheum Dis. 2011 Nov;70(11):2029-36
pubmed: 21803750
Drug Metab Lett. 2016;10(1):38-48
pubmed: 26693854
N Engl J Med. 2019 Jul 18;381(3):291-293
pubmed: 31314977
Ann Neurol. 2005 May;57(5):664-78
pubmed: 15852401
Br J Dermatol. 2015 Oct;173(4):969-74
pubmed: 25994337
Auto Immun Highlights. 2014 Aug 23;5(3):69-75
pubmed: 26000158
Immunity. 2006 Sep;25(3):343-8
pubmed: 16979566
J Immunol. 2011 Apr 1;186(7):4234-43
pubmed: 21383241
Rheumatology (Oxford). 2018 Dec 1;57(12):2114-2119
pubmed: 30060040
Genomics. 1996 Oct 1;37(1):57-61
pubmed: 8921370
Annu Rev Med. 2015;66:311-28
pubmed: 25587654
Nat Rev Immunol. 2005 May;5(5):375-86
pubmed: 15864272
Nat Rev Immunol. 2014 Jan;14(1):36-49
pubmed: 24362405
J Immunol. 2002 Apr 15;168(8):4154-63
pubmed: 11937576
J Rheumatol. 2005 Sep;32(9):1719-26
pubmed: 16142867
Lancet Neurol. 2018 Sep;17(9):816-828
pubmed: 30129477
Annu Rev Immunol. 1998;16:293-322
pubmed: 9597132
J Leukoc Biol. 2009 Jul;86(1):23-32
pubmed: 19304895
Science. 1995 Nov 3;270(5237):797-800
pubmed: 7481768
Clin Gastroenterol Hepatol. 2014 Sep;12(9):1485-93.e2
pubmed: 24480677
Lancet. 2017 Jan 21;389(10066):266-275
pubmed: 27988142
Expert Opin Investig Drugs. 2020 May;29(5):423-427
pubmed: 32293938
Brain. 2018 Nov 1;141(11):e80
pubmed: 30335130
Arthritis Rheum. 2005 May;52(5):1571-6
pubmed: 15880816
J Allergy Clin Immunol. 2021 Mar;147(3):814-826
pubmed: 33129886
Rheumatology (Oxford). 2021 Apr 6;60(4):1700-1707
pubmed: 33024992
Ann Rheum Dis. 2021 Mar;80(3):406-408
pubmed: 32843325
Clin Immunol. 2006 Sep;120(3):319-25
pubmed: 16859997
Arthritis Res Ther. 2010;12 Suppl 1:S1
pubmed: 20392288